Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Review
Oncology
Daniel Eiger, Elisa Agostinetto, Rita Saude-Conde, Evandro de Azambuja
Summary: The article discusses the expression of HER2 in breast cancer and the development of drugs targeting HER2. Patients with HER2-positive breast cancer have higher chances of cure and survival, and now there are also treatments available for patients with lower levels of HER2 expression.
Review
Genetics & Heredity
Mariana K. Najjar, Sara G. Manore, Angelina T. Regua, Hui-Wen Lo
Summary: HER2 overexpression is associated with poor prognosis in breast cancer, with HER2-targeted therapies, such as antibody-drug conjugates (ADCs), showing promising results in treating HER2-positive breast cancer. The development of ADCs leveraging the high specificity of HER2-targeted monoclonal antibodies with cytotoxic small molecules represents a significant advancement in the management of the disease.
Article
Cell Biology
Yujing Li, Yifan Sun, Michael Kulke, Torsten Hechler, Kevin Van der Jeught, Tianhan Dong, Bin He, Kathy D. Miller, Milan Radovich, Bryan P. Schneider, Andreas Pahl, Xinna Zhang, Xiongbin Lu
Summary: The heterozygous loss of chromosome 17p, a common genomic event in breast cancer, leads to global gene expression changes, reduced T cell tumor infiltration, and deletion of tumor suppressor genes like TP53. This loss also makes breast cancer cells sensitive to POLR2A inhibition, enabling targeted precision immunotherapy.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Ariella B. Hanker, Benjamin P. Brown, Jens Meiler, Arnaldo Marin, Harikrishna S. Jayanthan, Dan Ye, Chang-Ching Lin, Hiroaki Akamatsu, Kyung-Min Lee, Sumanta Chatterjee, Dhivya R. Sudhan, Alberto Servetto, Monica Red Brewer, James P. Koch, Jonathan H. Sheehan, Jie He, Alshad S. Lalani, Carlos L. Arteaga
Summary: The study found that the frequent HER3(E928G) kinase domain mutation increases the affinity of HER2/HER3 and reduces the binding of HER2 to its inhibitor neratinib. Co-expression of mutant HER2/HER3 enhances HER2/HER3 co-immunoprecipitation and ligand-independent activation of HER2/HER3 and PI3K/AKT, leading to increased growth, invasiveness, and resistance to HER2-targeted therapies, which can be reversed by combined treatment with PI3K alpha inhibitors.
Review
Biochemistry & Molecular Biology
Eleni Triantafyllidi, John K. Triantafillidis
Summary: Trastuzumab biosimilars have shown significant advantages in the treatment of HER-positive breast cancer, particularly in cases of metastatic breast cancer. This systematic review provides valuable insights into the efficacy, safety, and cost-benefit ratio of available trastuzumab biosimilars, but further research is needed to assess cost-effectiveness and the success rate of combination therapies with other anticancer drugs.
Article
Cell Biology
Marcia R. Campbell, Ana Ruiz-Saenz, Yuntian Zhang, Elliott Peterson, Veronica Steri, Julie Oeffinger, Maryjo Sampang, Natalia Jura, Mark M. Moasser
Summary: This article presents an extensive structure-function analysis of HER2 and HER3 signaling in cancer treatment. It reveals that the extracellular domains (ECDs) of these receptors are not essential for tumorigenic signaling and their conformational changes do not affect the dimerization interface. Additionally, disruptive receptor engineering fails to disturb tumorigenic signaling. The overexpression of HER2 uncouples intracellular signaling from extracellular constraints.
Article
Oncology
Luciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, Debora Maciel Santana, Erick Figueiredo Saldanha, Paula Tavares Guimaraes, Daniella Dias Silva Sa, Maria Fernanda Evangelista Simoes, Rafael Lima Viana, Francisca Giselle Rocha, Simone Klog Loose, Sinara Figueiredo Silva, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Fernando Augusto Batista Campos, Solange Moraes Sanches, Vladmir Claudio Cordeiro de Lima, Noam Falbel Ponde
Summary: Our study does not support HER2-low as a biologically distinct subtype of breast cancer, showing no prognostic value on survival outcomes and no predictive effect for pathological complete response after conventional neoadjuvant chemotherapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Biotechnology & Applied Microbiology
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Summary: The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2(+) breast cancer. Here, Swain et al. review the current standard of care for HER2(+) breast cancer, describe mechanisms of drug resistance, and focus on next-generation platforms and therapies for the treatment of this disease.
NATURE REVIEWS DRUG DISCOVERY
(2023)
Article
Oncology
Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchio, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purdie, Dave Purnell, Sarah E. Pinder, Ian O. Ellis, Andrew H. S. Lee
Summary: The ASCO/CAP guidance on HER2 testing in breast cancer has changed recently, leading to the re-classification of Group 2 tumors with specific characteristics. This study examined the response of Group 2 tumors to neoadjuvant chemotherapy. Results showed a higher pCR rate in Group 2 compared to combined Groups 4 + 5, indicating the need for further evaluation of HER2 Group 2 carcinomas for targeted therapy eligibility.
BRITISH JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Kelly McKenna, Stephen Willingham, Po Yi Ho, Benyamin Rosental, Michal Caspi Tal, Tal Raveh, Jens-Peter Volkmer, Mark D. Pegram, Irving L. Weissman
Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang
Summary: This study compared the efficacy and safety between novel anti-human epidermal growth factor receptor 2 antibody-drug conjugates (ADCs) and trastuzumab emtansine for patients with tyrosine kinase inhibitor (TKI) treatment failure. The results showed that both T-Dxd and other novel anti-HER2 ADCs had significantly better progression-free survival and objective response rate than T-DM1, with tolerable toxicities.
Article
Pharmacology & Pharmacy
Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen, Xi Yan
Summary: Through cost-effectiveness analysis, we found that T-DXd is more cost-effective than T-DM1 for patients with HER2-positive metastatic breast cancer in the US, but not in China at current drug prices.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Jessica Pougoue Ketchemen, Hanan Babeker, Anjong Florence Tikum, Anand Krishnan Nambisan, Fabrice Ngoh Njotu, Emmanuel Nwangele, Humphrey Fonge
Summary: Two domain-specific ADCs were developed and characterized in this study. The combination of these ADCs showed additive benefits, with lower IC50 and higher pharmacokinetics, indicating improved therapeutic effects against HER2.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Qin Li, Lei Zhang, XiuHong Li, Han Yan, Liuting Yang, Yingying Li, Teng Li, Jing Wang, Bangwei Cao
Article
Gastroenterology & Hepatology
Ying-Ying Li, Zheng-Ming Shi, Xiao-Yong Yu, Ping Feng, Xue-Jiang Wang
WORLD JOURNAL OF GASTROENTEROLOGY
(2016)
Article
Biochemistry & Molecular Biology
Ying-ying Li, Zheng-ming Shi, Xiao-tong Yu, Ping Feng, Xue-Jiang Wang
Article
Oncology
Hongchao Zhen, Liuting Yang, Li Li, Junxian Yu, Lei Zhao, Yingying Li, Qin Li
Article
Plant Sciences
Ying Jiang, Chi Wang, Ying-Ying Li, Xue-Cong Wang, Jian-Duo An, Yun-Jiao Wang, Xue-Jiang Wang
JOURNAL OF ETHNOPHARMACOLOGY
(2014)
Article
Microbiology
Yingying Li, Guangxiang Luo
Summary: HBV infection is a major global health issue, with current treatments being limited. Recent research has shown that LDLR plays a crucial role in HBV infection, suggesting potential new avenues for HBV therapy. Further studies are needed to explore the involvement of other LDLR family members in HBV infection.
Article
Engineering, Biomedical
Yingying Li, Xiaomin Jiang, Taokun Luo, Junjie Xia, Morten J. Lee, Ralph R. Weichselbaum, Wenbin Lin
Summary: This study reports the design of pIC nanoscale coordination polymer (NCP), pIC@NCP, and its potential to activate tumor-specific immune responses and synergize with ICB for potent antitumor effects. The results highlight the potential of NCP delivery of nucleic acid therapeutics for immune activation and cancer therapy.
Article
Pharmacology & Pharmacy
Yingying Li, Kaiyuan Ni, Christina Chan, Nining Guo, Taokun Luo, Wenbo Han, August Culbert, Ralph R. Weichselbaum, Wenbin Lin
Summary: The combination of radiotherapy (RT) and immunotherapy, along with DMAMCL sensitization, significantly enhances anti-cancer efficacy by increasing tumor-infiltrating CD4 and CD8 T cells, and establishing immune memory.
ADVANCED THERAPEUTICS
(2022)